Ranbaxy
Delhi HC attaches Ranbaxy promoters’ assets to enforce Daiichi award
26 Feb 2018
The court issued warrants of attachment on the assets of Malvinder Singh and Shivinder Singh, including shares, moveable and immovable property, art as well as debts owed to Oscar Investments and RHC Holding besides asking the Singh brothers to disclose all their assets
Daiichi case: thwarted in SC, Singhs may return to Singapore courts
17 Feb 2018
Brothers Malvinder and Shivinder Singh are “evaluating the option to challenge the ... award in Singapore courts” after the Supreme Court upheld a high court verdict that they must pay Daiichi Sankyo $546 million
Ranbaxy’s Singh bros must pay Daiichi Rs3,500 cr, rules HC
01 Feb 2018
In a petition filed at the Delhi HC, Daiichi had sought to enforce collection of Rs3,500-crore arbitration award it won at a Singapore tribunal in 2016 against Ranbaxy
Ranbaxy ex-bosses to challenge Rs2,562-cr fine for hiding info from Daiichi
06 May 2016
In a majority ruling this week, a three-member arbitration panel in Singapore imposed a fine on the billionaire brothers earlier this week in a case filed by Daiichi Sankyo in 2013
Former Ranbaxy promoters ordered to pay Rs2,500 cr damages
06 May 2016
Daiichi filed an arbitration case in 2013 in Singapore, accusing the Indian promoters of concealment and misrepresentation of facts and seeking compensation for fines that it was forced to pay the US Department of Justice
Sun, Ranbaxy complete $4-bn merger
24 Mar 2015
On Tuesday, the Reserve Bank of India approved the issue of equity shares of Sun Pharma to non-resident holders of equity shares of Ranbaxy, facilitating the merger through a scheme of arrangement
Sun Pharma buyout of Ranbaxy gets conditional US nod
31 Jan 2015
Fearing that the $4-billion deal would be anti-competitive, the FTC has stipulated that Sun sell its interest in a generic anti-bacterial medicine
Sun Pharma, Ranbaxy merger deal gets conditional CCI nod
09 Dec 2014
The CCI has asked the two companies to sell off seven brands with combined sales of less than Rs50 crore and market share of 60 to 80 per cent, which the regulator felt, would adversely affect competition
US court dumps Ranbaxy’s bid to stall launch of rival generics
20 Nov 2014
Ranbaxy’s move is seen as risky especially since the drug maker has been under regulatory probe for a long period now
Ranbaxy sues US FDA over revoking drug approvals
18 Nov 2014
Generic Nexium and Valcyte together would have contributed about $200 million to Ranbaxy's revenue in the first six months of market exclusivity, say analysts
Ranbaxy grilled by US Justice Dept over Medicaid drug pricing
18 Sep 2014
The US Justice Department has requested Ranbaxy for documents and information through a civil investigative demand, though it does not allege any wrongdoing
US judge upholds Ranbaxy-Pfizer Lipitor marketing deal
13 Sep 2014
In a piece of good news for the US FDA-challenged Ranbaxy laboratories, a US court has dismissed an anti-trust suit against Pfizer Inc and India's Ranbaxy that accused them of conspiring to delay sales of generic versions of the cholesterol drug Lipitor
Sun-Ranbaxy merger: competition panel demands more details
28 Aug 2014
This is probably the first instance where the fair trade watchdog has ordered a public scrutiny of a proposed merger and acquisition deal to ensure compliance to fair trade regulation
Ranbaxy faces fresh US penalty of Rs242 cr over Toansa-made API
22 Aug 2014
This is the second such penalty for the company, which paid $500 million to the US department of justice (DoJ) in May 201
Featured articles
Lighter than air, yet very, very powerful
By Kiron Kasbekar | 03 Jan 2024
In March 2013 Chinese scientists pulled off a remarkable feat. They created the world’s lightest aerogel. Tipping the scales at a mere 0.16 milligrams per cubic centimeter – that’s a sixth of the weight of air!
COP28 explained: A closer look at COP28's climate change solutions
By Aniket Gupta | 27 Dec 2023
The 28th United Nations Climate Change Conference, also known as COP28, took place from 30th November 2023, to 13th December 2023, at Expo City in Dubai, United Arab Emirates.
What is a Ponzi scheme?
By Aniket Gupta | 06 Dec 2023
Ponzi schemes have long captivated the public imagination, drawing unsuspecting investors into a web of illusion and deception.
The Rise and Rise of HDFC Bank
03 Jul 2023
HDFC, which surged ahead of global majors like HSBC Holdings Plc and Citigroup Inc and left Indian peers like State Bank of India and ICICI Bank in market capitalisation, now ranks fourth largest among the world’s most valuable banks, after JPMorgan Chase & Co, Industrial and Commercial Bank of China Ltd and Bank of America Corp
India’s Millet Revolution To Enrich Global Food Basket
02 Apr 2023
Millets, a healthier and cheaper substitute to wheat and rice, are indigenous to many parts of the world, especially in the semiarid tropics of Asia and Africa, and offers a big scope for expanding production and consumption in the foodgrain deficient African continent
Market predator Hindenburg preys on Adani stock
06 Mar 2023
Almost a month after the damning report of short-seller Hindenburg Research on the Adani Group that claimed that the seven stocks within the group were about 85 per cent overvalued, one of the group's stocks, Adani Total Gas, closed at Rs835 on the BSE, down nearly 79 per cent from its 24 January level, almost close to reaching that valuation
